Live
FierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC gameClinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?Clinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting MicrogliaEndpoints NewsFDA gives rejected drugs another chance in post-Makary eraClinical OMICsAI Discovers Two New Antibiotics for Drug-Resistant GonorrheaClinical OMICsGLP-1 Drugs Reduce Crime-Linked BehaviorClinical OMICsMacrophage EGFR Activity Linked to Immune Suppression, Tumor Growth in Colorectal CancerClinical OMICsUnexpected Role for RNA Editing in Cancer Immune Evasion UncoveredClinical OMICsProactive Surveillance Pays Off for Patients with Li-Fraumeni SyndromeClinical OMICsCAR T Success Hinges on Microenvironment Response in GBMEndpoints NewsFDA warns telehealth companies over compounded GLP-1sBioPharma DiveUniQure to file gene therapy for approval, reflecting major shifts at FDA
eLife Jan 28, 2026

Global risk mapping of highly pathogenic avian influenza H5N1 and H5Nx in the light of epidemic episodes occurring from 2020 onwards

Global risk mapping of highly pathogenic avian influenza H5N1 and H5Nx in the light of epidemic episodes occurring from 2020 onwards

Original
Body unavailable. Use the original source.